SG Americas Securities’s Trevi Therapeutics TRVI Stock Holding History

SG Americas Securities’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Sell	6,325 -21,726	-77%	-$316K	﹤0.01%	3040
2026 Q1	$335K	Sell	28,051 -96,511	-77%	-$1.08M	﹤0.01%	2400
2025 Q4	$1.56M	Buy	124,562 +60,017	+93%	+$694K	﹤0.01%	1689
2025 Q3	$591K	Buy	+64,545	New	+$484K	﹤0.01%	1975
2025 Q2	–	Sell	-24,661	Closed	-$155K	–	3599
2025 Q1	$155K	Sell	24,661 -2,131	-8%	-$10.2K	﹤0.01%	2723
2024 Q4	$110K	Buy	26,792 +3,387	+14%	+$10.8K	﹤0.01%	2674
2024 Q3	$78K	Buy	+23,405	New	+$69.6K	﹤0.01%	3144
2024 Q2	–	Sell	-14,592	Closed	-$50K	–	3315
2024 Q1	$50K	Sell	14,592 -83,661	-85%	-$187K	﹤0.01%	2769
2023 Q4	$132K	Buy	98,253 +78,656	+401%	+$119K	﹤0.01%	2525
2023 Q3	$43K	Buy	+19,597	New	+$44.3K	﹤0.01%	2972

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

SG Americas Securities's TRVI Position: Q2 2026 in Review

SG Americas Securities reduced its Trevi Therapeutics (TRVI) stake by 77% in Q2 2026, selling an estimated $316K and leaving 6,325 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

SG Americas Securities first reported a position in TRVI in Q3 2023 and has held it in 10 quarters since. The position peaked at $1.56M in Q4 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

SG Americas Securities held 6,325 shares of Trevi Therapeutics worth $118K as of Q2 2026.
SG Americas Securities sold 21,726 Trevi Therapeutics shares in Q2 2026, an estimated $316K.
Trevi Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3040 holding.
SG Americas Securities first reported a position in Trevi Therapeutics in Q3 2023 and has held it in 10 quarters since.
SG Americas Securities's Trevi Therapeutics position peaked at $1.56M in Q4 2025.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.